Seratonin release assay

Identifying only clinically relevant antibodies

Our serotonin release assay is the gold standard diagnostic test for detecting clinically relevant (platelet-activating) heparin-induced thrombocytopenia (HIT) antibodies. With high levels of sensitivity and specificity and timely turnaround times, our validated serotonin release assay is designed to guide care and improve outcomes for patients suspected of having HIT.

Seratonin release assay Test menu

Seratonin release assay

HIT is a rare but serious immune-mediated reaction to the drug heparin that can cause potentially fatal thromboembolism. While infrequent, HIT typically occurs within the first one to two weeks of a patient receiving heparin treatment, or rapidly upon heparin exposure in some patients with recent heparin therapy. Warning signs of HIT include a 50% or greater drop in platelet counts with or without thrombosis. 

Due to a number of clinical conditions that may mimic HIT and poor specificity of frontline HIT (PF4-polyanion) ELISAs, confirmation of diagnosis with a trusted functional assay is important to ensuring that only patients with HIT receive HIT-directed therapies, such as non-heparin anticoagulants.

Key testing



Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.